Actome GmbH announces release of first commercial products

Actome has released the first commercial products to the EU market based on the Protein Interaction Coupling (PICO) Technology. The PICO assay kits for measuring proteins and protein interactions are available through our online webshop

Actome GmbH is a life-science startup form Freiburg adapting digital PCR (dPCR) technology for the ultra-sensitive measurement of proteins and protein interactions. Our first products based on the Protein Interaction Coupling (PICO) Technology enable the use of the QIAcuity dPCR product line of QIAGEN for measuring proteins and protein interactions. The assay kits contain all necessary materials for labeling of antibodies with the unique PICO Labels and to prepare the assay for readout by dPCR. Registered customers can use the Actome’s AMULATOR software free of charge to analyze proteins and protein interactions with hitherto unseen performance.

The unique performance of Actome’s products is based on the patented PICO Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA-barcodes. Therefore, a pair of antibodies is used that are labeled by DNA barcodes. These barcodes are then detected by the dPCR method and decoded by the proprietary AMULATOR software developed by Actome. “Our PICO assay kits expand the capabilities of the QIAcuity digital PCR platform by QIAGEN from nucleic acids to proteins and protein interactions. Using our products, molecular biological researchers can use dPCR not only for detection of DNA and RNA, but also for proteins and protein interactions alike. In a super sensitive, cost efficient and convenient way.” says Peter Koltay, co-founder, CEO, and head of sales & marketing.

Proteins control and direct biological processes through their interactions by which they determine our health and wellbeing. Unlike DNA and RNA, proteins are not a blueprint or a template for a functional biomolecule, but they carry, encompass and execute biological function in living organisms. Tools to study the protein interactions enable the understanding of cellular processes and open up an enormous potential for research, diagnostics, and therapies. Tackling these challenges, Actome’s innovative PICO Technology is a breakthrough that will revolutionize life science research and biomedicine.

Über die Actome GmbH

Actome is a privately held young life science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his startup experience and the excellent environment provided by the University of Freiburg and the Hahn-Schickard research institute in Freiburg. Actome provides assay kits, bioinformatics software, and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome – which is the complete set of all protein interaction in a biological organism – and to exploit these discoveries in pharmaceutical and molecular diagnostic products for personalized medicine. Actome’s first products target the research market in the field of molecular biology with a specific focus on assay-kits for multi-omics and single cell analysis.

Firmenkontakt und Herausgeber der Meldung:

Actome GmbH
Georges-Köhler-Allee 103
79110 Freiburg im Breisgau
Telefon: +49 (1577) 2419732

Dr. Peter Koltay
Telefon: +49 (761) 203-73240
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.